These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 37980911)

  • 1. Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Moodliar R; Dodd M; Solodovnikova V; Liverko I; Rajaram S; Rassool M; McHugh T; Spigelman M; Moore DA; Ritmeijer K; du Cros P; Fielding K;
    Lancet Respir Med; 2024 Feb; 12(2):117-128. PubMed ID: 37980911
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TB-PRACTECAL: study protocol for a randomised, controlled, open-label, phase II-III trial to evaluate the safety and efficacy of regimens containing bedaquiline and pretomanid for the treatment of adult patients with pulmonary multidrug-resistant tuberculosis.
    Berry C; du Cros P; Fielding K; Gajewski S; Kazounis E; McHugh TD; Merle C; Motta I; Moore DAJ; Nyang'wa BT
    Trials; 2022 Jun; 23(1):484. PubMed ID: 35698158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A 24-Week, All-Oral Regimen for Rifampin-Resistant Tuberculosis.
    Nyang'wa BT; Berry C; Kazounis E; Motta I; Parpieva N; Tigay Z; Solodovnikova V; Liverko I; Moodliar R; Dodd M; Ngubane N; Rassool M; McHugh TD; Spigelman M; Moore DAJ; Ritmeijer K; du Cros P; Fielding K;
    N Engl J Med; 2022 Dec; 387(25):2331-2343. PubMed ID: 36546625
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
    Tweed CD; Dawson R; Burger DA; Conradie A; Crook AM; Mendel CM; Conradie F; Diacon AH; Ntinginya NE; Everitt DE; Haraka F; Li M; van Niekerk CH; Okwera A; Rassool MS; Reither K; Sebe MA; Staples S; Variava E; Spigelman M
    Lancet Respir Med; 2019 Dec; 7(12):1048-1058. PubMed ID: 31732485
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact and cost-effectiveness of the 6-month BPaLM regimen for rifampicin-resistant tuberculosis in Moldova: A mathematical modeling analysis.
    James LP; Klaassen F; Sweeney S; Furin J; Franke MF; Yaesoubi R; Chesov D; Ciobanu N; Codreanu A; Crudu V; Cohen T; Menzies NA
    PLoS Med; 2024 May; 21(5):e1004401. PubMed ID: 38701084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Motta I; Cusinato M; Ludman AJ; Lachenal N; Dodd M; Soe M; Abdrasuliev T; Usmanova R; Butabekov I; Nikolaevna TZ; Liverko I; Parpieva N; Moodliar R; Solodovnikova V; Kazounis E; Nyang'wa B-T; Fielding KL; Berry C
    Antimicrob Agents Chemother; 2024 Jul; 68(7):e0053624. PubMed ID: 38842323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial.
    Cevik M; Thompson LC; Upton C; Rolla VC; Malahleha M; Mmbaga B; Ngubane N; Abu Bakar Z; Rassool M; Variava E; Dawson R; Staples S; Lalloo U; Louw C; Conradie F; Eristavi M; Samoilova A; Skornyakov SN; Ntinginya NE; Haraka F; Praygod G; Mayanja-Kizza H; Caoili J; Balanag V; Dalcolmo MP; McHugh T; Hunt R; Solanki P; Bateson A; Crook AM; Fabiane S; Timm J; Sun E; Spigelman M; Sloan DJ; Gillespie SH;
    Lancet Infect Dis; 2024 Sep; 24(9):1003-1014. PubMed ID: 38768617
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
    Goodall RL; Meredith SK; Nunn AJ; Bayissa A; Bhatnagar AK; Bronson G; Chiang CY; Conradie F; Gurumurthy M; Kirenga B; Kiria N; Meressa D; Moodliar R; Narendran G; Ngubane N; Rassool M; Sanders K; Solanki R; Squire SB; Torrea G; Tsogt B; Tudor E; Van Deun A; Rusen ID;
    Lancet; 2022 Nov; 400(10366):1858-1868. PubMed ID: 36368336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
    Dooley KE; Rosenkranz SL; Conradie F; Moran L; Hafner R; von Groote-Bidlingmaier F; Lama JR; Shenje J; De Los Rios J; Comins K; Morganroth J; Diacon AH; Cramer YS; Donahue K; Maartens G;
    Lancet Infect Dis; 2021 Jul; 21(7):975-983. PubMed ID: 33587897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose, short-duration versus standard rifampicin for tuberculosis preventive treatment: a partially blinded, three-arm, non-inferiority, randomised, controlled trial.
    Ruslami R; Fregonese F; Apriani L; Barss L; Bedingfield N; Chiang V; Cook VJ; Fisher D; Flores E; Fox GJ; Johnston J; Lim RK; Long R; Paulsen C; Nguyen TA; Nhung NV; Gibson D; Valiquette C; Benedetti A; Menzies D
    Lancet Respir Med; 2024 Jun; 12(6):433-443. PubMed ID: 38552659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Availability of drugs and resistance testing for bedaquiline, pretomanid, linezolid, and moxifloxacin (BPaL(M)) regimen for rifampicin-resistant tuberculosis in Europe.
    Günther G; Guglielmetti L; Kherabi Y; Duarte R; Lange C;
    Clin Microbiol Infect; 2024 Sep; 30(9):1197.e1-1197.e4. PubMed ID: 38490355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.
    Dawson R; Diacon AH; Everitt D; van Niekerk C; Donald PR; Burger DA; Schall R; Spigelman M; Conradie A; Eisenach K; Venter A; Ive P; Page-Shipp L; Variava E; Reither K; Ntinginya NE; Pym A; von Groote-Bidlingmaier F; Mendel CM
    Lancet; 2015 May; 385(9979):1738-1747. PubMed ID: 25795076
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2/3 non-inferiority trial in South Korea.
    Mok J; Lee M; Kim DK; Kim JS; Jhun BW; Jo KW; Jeon D; Lee T; Lee JY; Park JS; Lee SH; Kang YA; Lee JK; Kwak N; Ahn JH; Shim TS; Kim SY; Kim S; Kim K; Seok KH; Yoon S; Kim YR; Kim J; Yim D; Hahn S; Cho SN; Yim JJ;
    Lancet; 2022 Oct; 400(10362):1522-1530. PubMed ID: 36522208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin adjunctive therapy for rifampicin-susceptible pulmonary tuberculosis: a phase 2b, randomised, open-label, multicentre trial.
    Cross GB; Sari IP; Kityo C; Lu Q; Pokharkar Y; Moorakonda RB; Thi HN; Do Q; Dalay VB; Gutierrez E; Balanag VM; Castillo RJ; Mugerwa H; Fanusi F; Kwan P; Chew KL; Paton NI;
    Lancet Infect Dis; 2023 Jul; 23(7):847-855. PubMed ID: 36966799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating newly approved drugs in combination regimens for multidrug-resistant tuberculosis with fluoroquinolone resistance (endTB-Q): study protocol for a multi-country randomized controlled trial.
    Patil SB; Tamirat M; Khazhidinov K; Ardizzoni E; Atger M; Austin A; Baudin E; Bekhit M; Bektasov S; Berikova E; Bonnet M; Caboclo R; Chaudhry M; Chavan V; Cloez S; Coit J; Coutisson S; Dakenova Z; De Jong BC; Delifer C; Demaisons S; Do JM; Dos Santos Tozzi D; Ducher V; Ferlazzo G; Gouillou M; Khan U; Kunda M; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moreau M; Moschioni M; Nahid P; Osso E; Oyewusi L; Panda S; Pâquet A; Thuong Huu P; Pichon L; Rich ML; Rupasinghe P; Salahuddin N; Sanchez Garavito E; Seung KJ; Velásquez GE; Vallet M; Varaine F; Yuya-Septoh FJ; Mitnick CD; Guglielmetti L
    Trials; 2023 Nov; 24(1):773. PubMed ID: 38037119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
    Boeree MJ; Heinrich N; Aarnoutse R; Diacon AH; Dawson R; Rehal S; Kibiki GS; Churchyard G; Sanne I; Ntinginya NE; Minja LT; Hunt RD; Charalambous S; Hanekom M; Semvua HH; Mpagama SG; Manyama C; Mtafya B; Reither K; Wallis RS; Venter A; Narunsky K; Mekota A; Henne S; Colbers A; van Balen GP; Gillespie SH; Phillips PPJ; Hoelscher M;
    Lancet Infect Dis; 2017 Jan; 17(1):39-49. PubMed ID: 28100438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis.
    Sweeney S; Berry C; Kazounis E; Motta I; Vassall A; Dodd M; Fielding K; Nyang'wa BT
    PLOS Glob Public Health; 2022; 2(12):e0001337. PubMed ID: 36962909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Safety and Tolerability of Linezolid in Novel Short-Course Regimens Containing Bedaquiline, Pretomanid, and Linezolid to Treat Rifampicin-Resistant Tuberculosis: An Individual Patient Data Meta-analysis.
    Hasan T; Medcalf E; Nyang'wa BT; Egizi E; Berry C; Dodd M; Foraida S; Gegia M; Li M; Mirzayev F; Morgan H; Motta I; Nguyen L; Schumacher S; Schlub T; Fox G
    Clin Infect Dis; 2024 Mar; 78(3):730-741. PubMed ID: 37874021
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
    Guglielmetti L; Ardizzoni E; Atger M; Baudin E; Berikova E; Bonnet M; Chang E; Cloez S; Coit JM; Cox V; de Jong BC; Delifer C; Do JM; Tozzi DDS; Ducher V; Ferlazzo G; Gouillou M; Khan A; Khan U; Lachenal N; LaHood AN; Lecca L; Mazmanian M; McIlleron H; Moschioni M; O'Brien K; Okunbor O; Oyewusi L; Panda S; Patil SB; Phillips PPJ; Pichon L; Rupasinghe P; Rich ML; Saluhuddin N; Seung KJ; Tamirat M; Trippa L; Cellamare M; Velásquez GE; Wasserman S; Zimetbaum PJ; Varaine F; Mitnick CD
    Trials; 2021 Sep; 22(1):651. PubMed ID: 34563240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
    De Castro N; Marcy O; Chazallon C; Messou E; Eholié S; N'takpe JB; Bhatt N; Khosa C; Timana Massango I; Laureillard D; Chau GD; Domergue A; Veloso V; Escada R; Wagner Cardoso S; Delaugerre C; Anglaret X; Molina JM; Grinsztejn B;
    Lancet Infect Dis; 2021 Jun; 21(6):813-822. PubMed ID: 33667406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.